CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 17 enrolled
Drug / intervention
CERC-501 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02800928
NCT02800928Phase 2Completed
CompareCT.gov

Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?

Yale University·interventional·Posted Jun 15, 2016·Updated Aug 13, 2019

In Brief

A Phase 2 clinical trial evaluating CERC-501 and Placebo for Smoking. Completed, enrolled 17 participants across 1 site.

Detailed Summary

A Randomized, Double-Blind, Placebo-Controlled, Crossover Design Study of CERC-501 in a Human Laboratory Model of Stress-precipitated Smoking Behavior.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA), Office of Research on Women's Health (ORWH), Janssen Pharmaceuticals

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 15, 2016
Enrollment StartJun 30, 2016
Primary CompletionJan 2, 2018
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 10.0 years ago

Interventions

CERC-501drug

CERC-501

Placebodrug

Placebo